Innovent Biologics Unveils Promising Data on IBI3055 for Autoimmune Treatment at Summit 2026 Innovent Biologics presents preclinical results of IBI3055, a tri-specific T cell engager aimed at treating autoimmune diseases, at the Immune Resetting Summit 2026.

Innovent Biologics Unveils Promising Data on IBI3055 for Autoimmune Treatment at Summit 2026 #China #Suzhou #Innovent_Biologics #IBI3055 #T_Cell_Engager

Antibody Therapeutics(IF=4.5, Oxford University Press)
🎇🎇Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy
academic.oup.com/abt/article/...
#Bispecific #T_cell_engager